Zerbor
Evofem Biosciences (NASDAQ:EVFM) inventory soared ~31% publish market on Aug. 4 after Q2 web loss narrowed and the ladies well being firm reaffirmed its FY22 product gross sales outlook.
Q2 web gross sales of contraception vaginal gel Phexxi grew +42% Q/Q to $6M. The corporate stated the enhance mirrored increased ex-factory gross sales and decrease gross-to-net changes of 40% for Q2 2022.
“We anticipate ongoing progress will likely be pushed by our gross sales and advertising and marketing initiatives, in addition to market entry enlargement as payers and PBMs proceed so as to add Phexxi to their formularies with no restrictions to adjust to federal steering,” stated Evofem CEO Saundra Pelletier.
The corporate was additionally trying ahead to report knowledge in October from a part 3 trial of Phexxi to stop chlamydia and gonorrhea, Pelletier famous.
Web loss from operations improved 16% Q/Q to -$24.4M. Whole working bills decreased to $30.5M, in comparison with $33.2M within the Q1 2022.
At June 30, the corporate had $19.9M in unrestricted money and $1.6M in restricted money, in comparison with $7.7M of unrestricted money and $5.1M of restricted money at Dec. 31, 2021.
Outlook:
Evofem stated it continues to anticipate web product gross sales within the vary of $30M to $35M for FY22, a progress of +264% to +325% Y/Y. Consensus Income Estimate for 2022 is $31.34M.
The corporate added that gross-to-net is anticipated to be 40% or higher, trending towards the decrease in H2 2022.
Evofem famous that it stays on observe to fulfill its aim of decreasing prices by $50M in 2022; complete working bills have been $25.3M decrease in H1 2022, in comparison with identical interval a 12 months in the past.
EVFM +26.95% to $1.14 publish market Aug. 4
